Cytokinetics Offers Update on Development Program for Tirasemtiv By: Benzinga via Benzinga October 20, 2014 at 07:33 AM EDT Cytokinetics, Incorporated (Nasdaq: CYTK) provided a program update today relating to tirasemtiv, the company's lead drug candidate ... Read More >> Related Stocks: Cytokinetics